TAK

Phase 3 Clinical Trial Initiation: Keros Therapeutics has begun the Phase 3 RENEW clinical trial for elritercept in adults with transfusion-dependent anemia, marking a significant milestone that triggers a $10 million payment from Takeda.

Financial Agreement with Takeda: Under a licensing agreement with Takeda, Keros received a $200 million upfront payment and is eligible for additional milestones that could exceed $1.1 billion for the development and commercialization of elritercept outside certain regions.

New Director Assignments: Takeda has announced new assignments for its Board of Directors, which includes 11 external directors out of a total of 14 members, emphasizing strong governance and transparency. The Audit and Supervisory Committee, Nomination Committee, and Compensation Committee will consist solely of external directors.

Company Mission and Governance: Takeda is committed to creating better health and advancing treatment options globally, guided by its values and robust corporate governance model, which is crucial for its success in the biopharmaceutical industry.

Approval of ADCETRIS: The European Commission has approved ADCETRIS (brentuximab vedotin) in combination with a chemotherapy regimen for adult patients with newly diagnosed Stage IIb/III/IV Hodgkin lymphoma, based on positive results from the Phase 3 HD21 trial demonstrating superior safety and efficacy compared to the standard treatment eBEACOPP.

Expanded Treatment Options: This approval marks the second indication for ADCETRIS in frontline Hodgkin lymphoma, enhancing its therapeutic reach within the European Union, where it is already approved for six other distinct indications.